BioGeneration closes third fund

European VC BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation -- JJDC Inc., plus the European Investment Fund (EIF), Schroder Adveq, and MAN Pension Trust.

BioGeneration invests in early stage therapeutics, diagnostics and medtech companies, with a focus on seed and series A financings in the Benelux and Germany...